China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115 million shares on the Shanghai Stock Exchange’s Science and Technology Innovation Board (STAR). The shares were priced at RMB 18.12 (USD 2.68) each, raising a total of RMB 2.08 billion (USD 308 million) and valuing the company at RMB 10.42 billion (USD 1.54 billion).
Company Profile
InventisBio is a global biotech company focused on the research and development (R&D) of innovative drugs, with a primary focus on cancer and metabolic diseases. The company closed an RMB 1 billion (USD 148 million) Series D financing round in September 2020.
Pipeline Highlights
- BPI-D0316: A third-generation EGFR TKI for non-small cell lung cancer, expected to file a New Drug Application (NDA) this year.
- D-0502: An ER degrader for breast cancer, currently in early clinical development.
- D-0120: A URAT1 inhibitor for gout, also in early clinical stages.
- D-1553: A KRAS G12C inhibitor targeting solid tumors, in early clinical development.
- Five pre-clinical programs targeting tumors, inflammatory diseases, and autoimmune diseases.-Fineline Info & Tech
